Figure 4 | British Journal of Cancer

Figure 4

From: Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01

Figure 4

Suppression of VA-mediated activation of NF-κB by Calphostin C (CC), Staurosporine (STP), UCN-01 or Parthenolide in H460, TE12 and H211 cells. Cells were transiently transfected with NF-κB-luciferase reporter plasmid and concurrently treated with VA (1 or 5 mM) in combination with CC (2 μ M), STP (200 nM), UCN-01 (500 nM) or Parthenolide (20 μ M). Cells were harvested 24 h after the onset of drug treatment and assayed for luciferase activity. Data are presented as fold increase of luciferase activity, normalised for cellular proteins, from baseline activity of untreated controls (means±s.e.m. of three independent experiments; +P<0.05–0.01 and #P<0.001 vs controls by ANOVA and pairwise comparison by Bonferroni test).

Back to article page